Orexin receptor antagonists for delirium prevention: systematic review in cancer
- 11 November 2025
- journal article
- review article
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 16 (2) , 322-324
Abstract
Orexin receptor antagonists promote sleep by blocking receptors for orexin, a neurotransmitter that maintains wakefulness. Pharmacological interventions for modifying sleep-wake cycle disturbances have recently garnered increased attention for the prevention of delirium, and previous studies have demonstrated the efficacy of melatonin receptor agonists in the prevention of delirium. Orexin receptor antagonists are also a promising intervention to prevent delirium by modifying the sleep-wake cycle, and several studies have examined the efficacy of orexin receptor antagonists, either alone or in combination with ramelteon, in preventing delirium, particularly in acutely ill patients.Keywords
This publication has 5 references indexed in Scilit:
- Dual Orexin Receptor Antagonists for Delirium: A Scoping Review and Feasibility Trial of DaridorexantJournal of the Academy of Consultation-Liaison Psychiatry, 2025
- Suvorexant for Reduction of Delirium in Older Adults After HospitalizationJAMA Network Open, 2024
- Suvorexant with or without ramelteon to prevent delirium: a systematic review and meta‐analysisPsychogeriatrics, 2021
- Suvorexant for the prevention of deliriumMedicine, 2020
- Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trialAcute Medicine & Surgery, 2018